Salarius Pharmaceuticals, Inc. (SLRX)
- Previous Close
0.4739 - Open
0.4653 - Bid --
- Ask --
- Day's Range
0.4511 - 0.4970 - 52 Week Range
0.4300 - 1.8690 - Volume
67,726 - Avg. Volume
115,129 - Market Cap (intraday)
2.34M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-3.8400 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.25
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
www.salariuspharma.comRecent News: SLRX
Performance Overview: SLRX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLRX
Valuation Measures
Market Cap
2.34M
Enterprise Value
-3.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-75.90%
Return on Equity (ttm)
-160.07%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.54M
Diluted EPS (ttm)
-3.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
5.9M
Total Debt/Equity (mrq)
5.48%
Levered Free Cash Flow (ttm)
-8.99M
Research Analysis: SLRX
Company Insights: SLRX
SLRX does not have Company Insights